This visual abstract depicts how Wei et al. utilize single - cell
phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.
Evan Paull, a graduate student in Stuart's lab at UC Santa Cruz (now at Columbia University), led the computational
analyses, which involved integrating the
phosphoproteomic data with genomic and gene expression datasets to provide a unified view of the activated signaling pathways in late stage prostate cancer.
He has also been leading statistical data
analysis for the Broad Institute's Proteome Characterization Center and Proteogenomic Data Analysis Center established under the National Cancer Institute Clinical Proteomics Tumor Analysis Consortium (CPTAC), focusing on proteogenomic analysis of proteomic, phosphoproteomic, and genomic data derived from cancer
analysis for the Broad Institute's Proteome Characterization Center and Proteogenomic Data
Analysis Center established under the National Cancer Institute Clinical Proteomics Tumor Analysis Consortium (CPTAC), focusing on proteogenomic analysis of proteomic, phosphoproteomic, and genomic data derived from cancer
Analysis Center established under the National Cancer Institute Clinical Proteomics Tumor
Analysis Consortium (CPTAC), focusing on proteogenomic analysis of proteomic, phosphoproteomic, and genomic data derived from cancer
Analysis Consortium (CPTAC), focusing on proteogenomic
analysis of proteomic, phosphoproteomic, and genomic data derived from cancer
analysis of proteomic,
phosphoproteomic, and genomic data derived from cancer samples.